PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Crawls 10,000+ sources around the clock and organizes the noise into verified stories — de-duplicated, bias-scored, and auto-tagged, with blindspot detection, trend analytics, anomaly alerts, translation, and custom digests or RSS. All in one live dashboard.

MedPage Today

healthCenter

4h ago

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapytranslating…

(MedPage Today) -- Survival in metastatic non-small cell lung cancer (NSCLC) did not improve with the addition of the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) to immunotherapy, a large randomized trial showed.
Median progression...

Factuality

74/100

Political Bias

Center

Ownership

MedPage Digital Media

Country

Unknown

Keywords#ADC#Addition#Immunotherapy#Metastatic#NSCLC

Read Original ↗

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy | Pulse Aggregator